| ||The safety and also scientific validity of this research is the responsibility of the research sponsor and also investigators. Listing a research does not typical it has actually been evaluated by the U.S. Commonwealth Government. Recognize the risks and potential benefits of clinical studies and talk to her health treatment provider prior to participating. Read our disclaimer for details.|
You are watching: Guillermo had a myocardial infarction; in other words, guillermo had a(n)
Top of page Study summary Study style Arms and also Interventions Outcome procedures Eligibility Criteria Contacts and also Locations more Information
This study will be the an initial trial to evaluate the safety and also efficacy the dapagliflozin therapy in staying clear of readmissions/ER visits/urgent clinic visits, and also death in patient with and also without T2D after admission for heart failure. Treatment v SGLT2-i has actually been shown to reduce both heart failure hospitalizations and mortality in patient with created heart disease. However, the moment of initiation of SGLT2-i therapy has not to be evaluated in patients with HF. In addition, the influence of therapy on HF symptoms top quality of life, resource utilization, and cost-effectiveness of dapagliflozin versus placebo will certainly be evaluated. The outcomes of this study have great potential to affect and facilitate care and also to change current clinical accuse in the administration of patients v heart failure.
|Heart fail Diabetes||Drug: Dapagliflozin Drug: Placebo||phase 4|
The prevalence of both heart failure and form 2 diabetes (T2D) or prediabetes are getting to epidemic proportions globally and also in the united States. More than 40% of patient with created heart failure (HF) have actually diabetes.
This examine will it is in the very first trial to advice the safety and also efficacy of dapagliflozin therapy in staying clear of readmissions/ER visits/urgent clinic visits, and death in patient with and without T2D after admission for heart failure. Treatment with SGLT2-i has been displayed to reduce both heart failure hospitalizations and also mortality in patients with established heart disease. However, the time of initiation the SGLT2-i therapy has actually not been evaluated in patients v HF. In addition, the impact of treatment on HF symptoms quality of life, source utilization, and cost-effectiveness the dapagliflozin versus placebo will be evaluated. The results of this examine have good potential to impact and facilitate care and also to adjust current clinical guidelines in the monitoring of patients v heart failure.
Top of page Study summary Study architecture Arms and Interventions Outcome measures Eligibility Criteria Contacts and also Locations more Information
See more: The Complete Clay Sanskrit Library : 56, Clay Sanskrit Library
|Study type :||Interventional (Clinical Trial)|
|EstimatedEnrollment :||392 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||twin (Participant, Outcomes Assessor)|
|Official Title:||Dapagliflozin Heart fail Readmission|
|Actual examine Start day :||July 29, 2020|
|estimated Primary Completion day :||July 2023|
|estimated Study Completion date :||July 2023|